Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch

Partnerships, mergers, business combinations, and acquisitions could all be on the horizon for the biotech.

Jul 25, 2023 - 20:00

Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch

Partnerships, mergers, business combinations, and acquisitions could all be on the horizon for the biotech.

Read the original article

Tags:

Previous Article

Statins reduce cardiovascular risk in people living with HIV, new global study f...

Astellas and PeptiDream enter protein degrader discovery deal

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: With weight loss drug ads, telehealth companies wade into a regulatory gray area

STAT+: With weight loss drug ads, telehealth companies ...

Apr 7, 2023

STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions

STAT+: At JPM, biotech’s most prolific dealmaker sees a...

Jan 8, 2024

NICE recommends Pfizer’s Ritlecitinib for alopecia areata treatment

NICE recommends Pfizer’s Ritlecitinib for alopecia area...

Feb 24, 2024